（预留授予日） | 人员类别 | | 获授的权益 | 占预留授予总量 | 占股本总额 | | --- | --- | --- | --- | --- | | | | 数量（万股） | 的比例 | 的比例 | | 中层管理人员（3 人） | | 2.7454 | 16.36% | 0.0043% | | 科研骨干与高技能人员（16 | 人） | 9.2955 | 55.40% | 0.0144% | | 业务骨干人员（12 人） | | 4.7383 | 28.24% | 0.0074% | | 合计 | | 16.7792 | 100.00% | 0.0261% | 一、预留授予总体情况 东阿阿胶股份有限公司 第一期限制性股票激励计划预留授予激励对象名单 | 二、中层、科研骨干与高技能人员及业务骨干 | | --- | | 序号 | 姓名 | 分类 | | --- | --- | --- | | 1 | 刘延风 | 中层、科研骨干与高技能人员、业务骨干 | | 2 | 解福生 | 中层、科研骨干与高技能人员、业务骨干 | | 3 | 任儒倬 | 中层、科研骨干与高技能人员、业务骨干 | | 4 | 曾立 | ...

北京金诚同达律师事务所 关于 东阿阿胶股份有限公司 第一期限制性股票激励计划预留部分授予事项的 法律意见书 中国北京市建国门外大街1号国贸大厦A座十层 100004 电话：010-5706 8585 传真：010-8515 0267 | | | 金诚同达律师事务所 法律意见书 释 义 在本法律意见书中，除非文中另有说明，下列词语具有下述涵义： | 东阿阿胶/公司 | 指 | 东阿阿胶股份有限公司 | | --- | --- | --- | | 本次激励计划 | 指 | 东阿阿胶股份有限公司第一期限制性股票激励计划 | | 限制性股票 | 指 | 公司根据本次激励计划规定的条件和价格，授予激励对象一定 数量的公司股票，该等股票设置一定期限的限售期，在达到本 | | | | 次激励计划规定的解除限售条件后，方可解除限售流通 | | 本次授予 | 指 | 本次激励计划预留部分授予 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《管理办法》 | 指 | 《上市公司股权激励管理办法》 | | 《公司章程》 | 指 | 《东阿阿胶股份有限公司章 ...

12月30日，东阿阿胶公告，公司拟向山东省教育基金会捐赠160万元（其中，现金150万元，实物折合10 万元）。 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-85 东阿阿胶股份有限公司 关于对外捐赠的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 二、对公司的影响 东阿阿胶股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召开第 十一届董事会第十六次会议，审议通过了《关于对外捐赠的议案》。现将有关情 况公告如下： 一、对外捐赠事项概述 为深化企地交流，助力地方教育事业高质量发展，公司拟向山东省教育基金 会捐赠 160 万元（其中，现金 150 万元，实物折合 10 万元）。根据《深圳证券 交易所股票上市规则》及《公司章程》等相关规定，本议案无需提交股东会审议。 本次对外捐赠受赠方为山东省教育基金会，与公司不存在关联关系，本次对 外捐赠不构成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重 大资产重组。 特此公告。 东阿阿胶股份有限公司 董 事 会 二〇二五年十二月三十一日 本次对外捐赠是公司积极履行社会责任的表现，对公司本期及未来财务状况 和经营成果不构成重大影响，不影响正常生产经营活动。 三、备查文件 1．第十一届董 ...

东阿阿胶股份有限公司 1．本次拟被授予限制性股票的激励对象，均具备《公司法》《证券法》等 法律法规和规范性文件以及《公司章程》规定的任职资格，符合《工作指引》《管 理办法》《深圳证券交易所股票上市规则》等法律法规和规范性文件及公司《激 励计划》规定的激励对象条件，不存在《管理办法》第八条规定的不得成为激励 对象的情形；激励对象中，无独立董事、单独或合计持有上市公司 5%以上股份 的股东或实际控制人及其配偶、父母、子女。本次被授予限制性股票的激励对象 主体资格合法、有效，满足获授限制性股票的条件。 2．本次预留授予激励对象的基本情况属实，不存在虚假、故意隐瞒或引起 重大误解之处。 东阿阿胶股份有限公司 董事会薪酬与考核委员会 二〇二五年十二月三十一日 董事会薪酬与考核委员会关于第一期限制性股票激励计划 预留授予激励对象的核查意见 根据《中央企业控股上市公司实施股权激励工作指引》（以下简称《工作指 引》）、《上市公司股权激励管理办法》（以下简称《管理办法》）及东阿阿胶 股份有限公司（以下简称"公司"）《第一期限制性股票激励计划（草案二次修 订稿）》（以下简称《激励计划》）等有关规定，公司董事会薪酬与考核委员会 对 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-83 东阿阿胶股份有限公司 第十一届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十六次 会议，于 2025 年 12 月 27 日以邮件方式发出会议通知。 4．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 本次会议审议并通过了以下议案： 1．《关于向第一期限制性股票激励计划激励对象授予预留部分限制性股票 的议案》 本议案提交董事会前，已经公司第十一届董事会薪酬与考核委员会审议通 过。 根据《上市公司股权激励管理办法》及《第一期限制性股票激励计划（草 案二次修订稿）》等有关规定以及公司 2024 年年度股东大会授权，董事会认为 本激励计划的预留授予条件已经满足，确定预留授予日为 2025 年 12 月 30 日， 向符合授予条件的 31 名激励对象授予 16.7792 万股限制性股票，授予价格为 29.29 元/股。 2 ...

Core Insights - The article emphasizes the increasing demand for Coenzyme Q10 due to common health issues such as chronic fatigue, cardiovascular concerns, and weakened immunity across all age groups [1][4] - The Coenzyme Q10 market faces challenges including purity fraud, rapid loss of activity, homogenized formulations, and inadequate safety certifications, leading to consumer confusion [1][4] - A quality upgrade in the Coenzyme Q10 industry is anticipated by 2025, with a focus on purity, stability, safety, and clinical evidence as key evaluation criteria [1][3] Industry Overview - The Coenzyme Q10 market is projected to evolve significantly by 2025, with a shift towards higher quality standards and consumer education on product selection [1][3] - The article introduces a "Top Ten High-Activity Coenzyme Q10 Recommendations" list, aimed at guiding consumers in making informed choices based on scientific data and third-party certifications [1][3] Product Highlights - **Jiang Yisheng**: Recognized for its breakthrough absorption technology, achieving a 98.6% absorption rate and leading the market with a 91% repurchase rate [4] - **Qi Yao Tang**: Focuses on targeted formulations for cardiovascular health and fatigue improvement, with an 88.3% effectiveness rate in fatigue relief [5] - **Tao Chen Bei Jian**: A domestic brand with a purity of 99.6%, offering a range of products suitable for various demographics, achieving an 86% repurchase rate [6] - **GNC**: Targets middle-aged consumers with a focus on heart health, featuring a 99.5% purity level and a gentle formulation [7] - **Swisse**: An Australian brand emphasizing active anti-aging properties, with a 40% improvement in antioxidant indicators after 8 weeks of use [8] - **Nutrabolt**: Caters to athletes with a high-content formula of 200mg per serving, achieving a 93% absorption rate [9] - **Xiu Zheng**: Combines traditional Chinese medicine with modern nutrition, focusing on cardiovascular health and energy replenishment [10] - **Yang Sheng Tang**: Offers a cost-effective option for daily supplementation, with a purity of 98.2% and a price point under 60 yuan [10] - **Centrum**: Provides a multi-nutrient approach suitable for all ages, with a focus on energy and bone health [11] - **Dong Ah Ejiao**: Targets postpartum recovery with a specialized formula, ensuring safety for breastfeeding mothers [12] Consumer Guidance - The article advises consumers to prioritize purity, activity assurance, and formulation suitability when selecting Coenzyme Q10 products [12] - It highlights the importance of understanding individual health needs and characteristics to make informed choices in the Coenzyme Q10 market [12]

Core Viewpoint - The seminar on the international dissemination of traditional Chinese medicine (TCM) culture, centered around the documentary "Four Seas TCM," highlights the importance of TCM's global outreach and its potential for cultural and economic development [3][4]. Group 1: Event Overview - The seminar titled "Building a New Path for International Dissemination of TCM Culture - Results of Season One of 'Four Seas TCM'" was held in Beijing on December 19 [3]. - The event featured prominent guests from policy research, media, data, academia, and industry, discussing the documentary's success and the core issues surrounding the global development of TCM [3]. Group 2: Key Insights from Speakers - Xu Wei, Chairman and CEO of Phoenix TV, emphasized that the internationalization of TCM is both a historical mission and a contemporary necessity, showcasing the dual benefits of brand promotion and cultural dissemination through quality content [3]. - Experts from the National Radio and Television Administration discussed innovative paths and practical values of the documentary in empowering TCM's international dissemination [3]. Group 3: Documentary Details - The documentary "Four Seas TCM," co-produced by Phoenix TV and Dong'e Ejiao, consists of 12 episodes and was meticulously produced over a year, set to air globally starting November 1, 2025 [4]. - The documentary has garnered significant attention, achieving over 2.6 billion interactions online, establishing a new benchmark for the international dissemination of TCM [4].

Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Core Viewpoint - The traditional Chinese medicine sector experienced a slight decline of 0.12% on December 26, with ST Bailin leading the drop, while the overall Shanghai Composite Index rose by 0.1% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3963.68, up 0.1% [1]. - The Shenzhen Component Index closed at 13603.89, up 0.54% [1]. - The traditional Chinese medicine sector saw a net outflow of 229 million yuan from major funds, while retail investors contributed a net inflow of 195 million yuan [2][3]. Group 2: Individual Stock Performance - Notable gainers included: - Zhongsheng Pharmaceutical (002317) with a closing price of 20.06, up 2.92% [1]. - Wanbangde (002082) closed at 13.70, up 2.09% [1]. - Tongrentang (600085) closed at 32.25, up 1.26% [1]. - Major decliners included: - ST Bailin (002424) closed at 4.59, down 4.97% [2]. - *ST Changyao (300391) closed at 1.47, down 3.92% [2]. - Jinhua Co. (600080) closed at 7.76, down 2.51% [2]. Group 3: Trading Volume and Capital Flow - Zhongsheng Pharmaceutical had a trading volume of 747,200 shares and a transaction value of 149 million yuan [1]. - ST Bailin had a trading volume of 849,300 shares with a transaction value of 391 million yuan [2]. - The capital flow data indicates that major funds had a net inflow in Zhongsheng Pharmaceutical, while other stocks like Tongrentang and Wanbangde saw mixed capital flows [3].